Skip to content

Establishing a New Ultrasound Technique to Improve Assessment of Chronic Kidney Disease.

Validation of Contrast Enhanced Ultrasound (CEUS) for the Assessment of Renal Perfusion Using Renal Magnetic Resonance Imaging (MRI) in Chronic Kidney Disease (CKD

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06159439
Enrollment
10
Registered
2023-12-06
Start date
2024-01-02
Completion date
2025-02-02
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Keywords

imaging, perfusion, contrast enhanced ultrasound

Brief summary

Blood flow to the kidneys is important in the development of kidney diseases. Currently we do not have ways of measuring and monitoring kidney blood flow for patients in real-time. This is a major barrier to investigation and management of acute kidney injury (AKI) and chronic kidney disease (CKD). Kidney blood flow can be reliably measured using a specialised type of MRI scan, but this is expensive and difficult to do in people who are unwell. Contrast-enhanced ultrasound (CEUS) is a new technique, which uses a contrast containing microbubbles to measure blood flow. The benefits of this method are that it is relatively inexpensive, the contrast agents are not kidney-damaging and it can be done at the bedside. We want to compare contrast enhanced ultrasound against the current best-measure of kidney blood flow, to see if it is giving accurate information about kidney blood flow. We will do this by doing both MRI and contrast enhanced ultrasound scans in people with chronic kidney disease and comparing the results.

Detailed description

Renal perfusion, the delivery of oxygenated blood to kidney tissues, is relevant to a number of acute and chronic kidney diseases. Despite this, we do not have methods in current clinical practice to measure renal perfusion and monitor the response to supportive treatments in real time. This is a major barrier to investigation and management of acute kidney injury (AKI) and chronic kidney disease (CKD). The current non-invasive gold standard technique for renal perfusion measurement is arterial-spin labelling magnetic resonance imaging (ASL-MRI), which has been validated against other measures of perfusion, including contrast agent-based methods. However, MRI has limitations including high cost, and logistical barriers. Therefore, validation of a bed-side measurement tool for renal perfusion would be of significant clinical importance. This proposal aims to validate CEUS renal cortical perfusion measurement by comparison with quantifiable ASL-MRI parameters of renal microvascular perfusion in individuals with CKD. TRIAL REGIMEN All interventions outlined below are for the purposes of research, not usual care. Study day: All participants will attend fasted for preceding 2 hours. Demographic details and medical history will be recorded. The patient's concomitant medications which form part of their usual care will be recorded. These will not be adjusted. Results of blood and urine tests that are collected as part of clinical care will be recorded. Participants will undergo two scanning sessions, the first using renal MRI at the Sir Peter Mansfield Imaging Centre (SPMIC) to provide a quantitative measure of renal perfusion, and the second to provide the comparator measure of renal perfusion using CEUS performed at Royal Derby Hospital. Outcomes: MRI derived perfusion variables: peak time, and peak signal intensity (SI) will be obtained from time intensity curves. Mean flow velocity (cm/s), cross-sectional area of the lumen (mm2), and hence bulk renal blood flow (ml/s) CEUS derived perfusion parameters: acoustic index (AU); mean transit time (seconds); perfusion index, which is the ratio of AI to mTT; and wash-in rate (seconds)

Interventions

Contrast enhanced ultrasound using Sonovue microbubble contrast

DIAGNOSTIC_TESTMRI scan

Arterial-spin labelling magnetic resonance imaging

Sponsors

University of Nottingham
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* CKD 3b or CKD4 * Ability to give informed consent

Exclusion criteria

* Autosomal dominant polycystic kidney disease * Solid organ transplant * Pregnant women * Known allergy to Sonovue * Contraindications to MRI

Design outcomes

Primary

MeasureTime frameDescription
Correlation between ASL-MRI measures of cortical perfusion (ml/ 100g/min) and CEUS measures of renal microvascular blood flow.MRI scan and contrast enhanced ultrasound scan to be performed within 7 days of each other.The primary outcome will be the correlation between ASL-MRI measures of cortical perfusion (ml/ 100g/min) and CEUS measures of renal microvascular blood flow. As CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used. We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.

Secondary

MeasureTime frameDescription
Repeatability of the CEUS measurements1 scanRepeatability of markers of perfusion between 5 flash-reperfusion sequences taken during 1 scan session
Correlation between global perfusion from PC-MRI corrected flow measures and CEUSMRI scan and CEUS done within 7 days of each otherAs CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used. We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.
Correlation between kinetic time-intensity parameters of CEUS and time-resolved MRAMRI scan and CEUS done within 7 days of each otherAs CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used. We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.

Contacts

Primary ContactKerry Horne, BMBCh
kerry.horne@nottingham.ac.uk07469037422

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026